GAIN THERAPEUTICS, INC
Income Statement
| Line Item | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Revenue | $55.2K | $140.1K | $165.0K | $28.9K |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | $11.5M | $8.4M | $7.2M | $2.3M |
| SG&A Expense | $10.8M | $9.5M | $6.8M | $1.2M |
| Operating Income | $-22.3M | $-17.8M | $-13.8M | $-3.5M |
| Operating Margin | -40,328.3% | -12,688.1% | -8,379.8% | -12,047.5% |
| Interest Expense | — | — | $0 | — |
| Pretax Income | $-22.2M | $-17.5M | $-13.9M | $-3.6M |
| Income Tax Expense | $79.3K | $93.0K | $4.0K | $5.4K |
| Net Income | $-22.3M | $-17.6M | $-13.9M | $-3.6M |
| Net Margin | -40,354.3% | -12,555.1% | -8,418.9% | -12,387.7% |
| EPS (Basic) | $-1.71 | $-1.48 | $-1.37 | $-0.33 |
| EPS (Diluted) | $-1.71 | $-1.48 | $-1.37 | $-0.33 |
| Shares Outstanding (Basic) | 13.0M | 11.9M | 10.2M | 10.7M |
| Shares Outstanding (Diluted) | 13.0M | 11.9M | 10.2M | 10.7M |
| Dividends Per Share | — | — | — | — |